Alprostadil for the treatment of impotence

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 3, 2014, Pages 421-428

  Hanchanale, Vishwanath ^a   Eardley, Ian ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Alprostadil; Erectile dysfunction; Impotence; Male; Phosphodiesterase 5 inhibitors; Therapy

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1;

ARTICLE; CANADA; DIABETES MELLITUS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERECTILE DYSFUNCTION; HUMAN; IMPOTENCE; MEDLINE; PELVIS SURGERY; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATECTOMY;

ALPROSTADIL; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84892765554     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.873789     Document Type: Article

References (53)

1. National Institutes of Health, NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993;270(1):83-90
2. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005;96(3):257-80
3. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000;12(Suppl 4):S6-11
4. Chew KK, Earle CM, Stuckey BG, et al. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000;12(1):41-5
5. Bacon CG, Mittleman MA, Kawachi I, et al. A prospective study of risk factors for erectile dysfunction. J Urol 2006;176(1):217-21
6. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54-61
7. Nehra A, Kulaksizoglu H. Global perspectives and controversies in the epidemiology of male erectile dysfunction. Curr Opin Urol 2002;12(6):493-6
8. Sommer F, Engelmann U. Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging 2004;21(9):555-64
9. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57(5):804-14
10. Virag R. Intracavernous injection of papaverine for erectile failure. 1982. J Urol 2002;167(2 Pt 2):1196
11. Brindley GS. Neuroprostheses used to restore male sexual or reproductive function. Baillieres Clin Neurol 1995;4(1):15-20
12. Ishii N, Watanabe H, Irisawa C, et al. Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence. Nihon Hinyokika Gakkai Zasshi 1986;77(6):954-62
13. Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 1988;140(3):525-7
14. Costa P, Potempa AJ. Intraurethral alprostadil for erectile dysfunction: a review of the literature. Drugs 2012;72(17):2243-54
15. Schanz S, Hauck EW, Schmelz HU, et al. Topical treatment of erectile dysfunction with prostaglandin E(1) ethyl ester. J Dtsch Dermatol Ges 2009;7(12):1055-9
16. Rooney M, Pfister W, Mahoney M, et al. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med 2009;6(2):520-34
17. Kim ED, McVary KT. Topical prostaglandin-E1 for the treatment of erectile dysfunction. J Urol 1995;153(6):1828-30
18. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75(1):191-236
19. Lea AP, Bryson HM, Balfour JA. Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Drugs Aging 1996;8(1):56-74
20. Kim N, Azadzoi KM, Goldstein I, et al. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991;88(1):112-18
21. Kirkham A. MRI of the penis. Br J Radiol 2012;85(Spec No 1):S86-93
22. Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie's disease: a nationwide survey. J Sex Med 2008;5(4):954-64
23. Godschalk MF, Chen J, Katz PG, et al. Treatment of erectile failure with prostaglandin E1: a double-blind, placebo-controlled, dose-response study. J Urol 1994;151(6):1530-2.
24. El-Sakka AI. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res 2006;18(2):180-5
25. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996;334(14):873-7.
26. Bechara A, Casabe A, Cheliz G, et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol 1997;157(6):2132-4
27. Gerber GS, Levine LA. Pharmacological erection program using prostaglandin E1. J Urol 1991;146(3):786-9
28. Shabsigh R, Padma-Nathan H, Gittleman M, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study. Urology 2000;55(1):109-13.
29. Shokeir AA, Alserafi MA, Mutabagani H. Intracavernosal versus intraurethral alprostadil: a prospective randomized study. BJU Int 1999;83(7):812-15
30. Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil-a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997;9(4):187-92
31. Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68(2):386-91.
32. Urciuoli R, Cantisani TA, Carlini M, et al. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2004(2):CD001784
33. Khera M, Goldstein I. Erectile dysfunction. Clin Evid (Online) 2011;2011
34. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7(1 Pt 2):524-40
35. Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998;160(4):1325-8
36. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338(20):1397-404
37. Jiang H, Xu QQ, Hong K, et al. Efficacy and safety of PGE1 cream in the treatment of erectile dysfunction. Zhonghua Nan Ke Xue 2003;9(2):97-9
38. Buvat J, Schupp J, Goldstein I, et al. Efficacy and safety of topical Aprostadil Cream (Vitaros-) in hypertensive, diabetic and cardiac patients with male erectile dysfunction (ED). 15th Congress of the European Society for Sexual Medicine; Amsterdam, Netherlands; 2012
39. Govier FE, McClure RD, Weissman RM, et al. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993;150(6):1822-4
40. Kulaksizoglu H, Hakim LS, Nehra A, et al. Comparison of alprostadil sterile powder (Caverject-) with trimix. Nomogram and patient satisfaction [abstract 699]. J Urol 1997;157(4 Suppl):180
41. McMahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999;162(6):1992-7; discussion 97-8
42. Nandipati K, Raina R, Agarwal A, et al. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res 2006;18(5):446-51
43. Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000;38(1):30-4
44. Nehra A, Jones WR, Hakim L, et al. Effectiveness of combination therapy of MUSE and Viagra in the salvage of erectile dysfunction patients desiring noninvasive therapy. J Urol 1999;161(4 Suppl):213
45. Chen J, Godschalk MF, Katz PG, et al. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction. J Urol 1995;153(5):1476-7
46. Limoge JP, Olins E, Henderson D, et al. Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety. J Urol 1996;155(4):1276-9
47. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med 2009;6(5):1232-47
48. Weinberg AE, Eisenberg M, Patel CJ, et al. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. J Sex Med 2013;10(12):3102-9
49. Yang G, Pan C, Lu J. Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. Int J Impot Res 2010;22(5):310-17
50. Hernandez-Mijares A, Garcia-Malpartida K, Sola-Izquierdo E, et al. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. J Sex Med 2010;7(5):1954-64
51. Lu CC. Smoking habits and erectile dysfunction in type 2 diabetic patients. J Sex Med 2010;7(4 Pt 1):1593
52. Awad H, Salem A, Gadalla A, et al. Erectile function in men with diabetes type 2: correlation with glycemic control. Int J Impot Res 2010;22(1):36-9
53. Perimenis P, Konstantinopoulos A, Perimeni PP, et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006;8(2):219-24